Cover Story Featured Article Product Launch Distribution Expansion Regulatory Milestone Study Results Bora Biologics and Protect Animal Health Partner to Advance Veterinary Antibody Pipeline Strategic Collaboration Bora Biologics and Protect Animal Health have entered a long-term, multi-pr...
Quick Takeaways: Why It Matters? Bora Biologics’ first animal‑health collaboration with Protect Animal Health gives Protect a U.S./Taiwan CDMO partner (CHO‑K1 cell line, process development, scale‑up, manufacturing) to advance at least three antibody programs (two mAbs, o...
Quick Takeaways: Why It Matters? ECO’s licence of Vaxinano’s late‑stage sheep toxoplasmosis vaccine gives it a low‑cost, de‑risked way to add a high‑value preventative product that directly tackles a major cause of abortion and lamb losses, with peak sales estimated a...
Quick Takeaways: Why It Matters? Boehringer Ingelheim’s purchase of Evax gives it a promising new way to treat common horse allergies with longer‑lasting vaccines instead of short‑term symptom relief, which could mean fewer vet visits and better outcomes for owners. If the approach works a...
Quick Takeaways: Why It Matters? If the science holds up, this could open a future premium category for hypoallergenic dogs and related breeding or licensing programs, creating new value in the pet biotech space while also raising major regulatory, ethical, and animal-welfare h...
Quick Takeaways: Why It Matters? By terminating the PrecisePRP arrangement with VetStem, PetVivo removes outstanding invoices, royalties and milestone overhangs from a non-core product line, which should simplify the story for investors and management while freeing attention and capital fo...
Quick Takeaways: Why It Matters? The deal strengthens Magapor’s ability to expand beyond its 60+ country footprint by adding growth capital for R&D, commercial expansion and product development in a niche but defensible livestock-reproduction category, while allowing the Mena Gericó fa...
Quick Takeaways: Why It Matters? PetVivo’s new study shows that a single intra-articular Spryng injection with OsteoCushion technology can improve pain and function in dogs with stifle osteoarthritis and suspected cranial cruciate disease. While the authors call for larger studies with obj...
Quick Takeaways: Why It Matters? Akston could emerge as a serious competitor in the fast-growing anti‑NGF OA segment that Zoetis currently leads with its once‑monthly monoclonal. Because Akston’s Ambifect approach stimulates sustained endogenous anti‑NGF antibody responses, AKS‑548d remain...
Quick Takeaways: Why It Matters? Full FDA approval for Laverdia transforms it from a conditionally approved option into the first fully approved oral, at‑home standard therapy for canine lymphoma, which should significantly boost veterinarian confidence and utilization via Dechra’s nationa...
